Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis-Reference-Cited by-同舟云学术

Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Graciaa Daniel S.¹^ORCID,Kipiani Maia²,Magee Matthew J.³⁴,Mikiashvili Lali²,Barbakadze Ketevan²,Bablishvili Nino²,Auld Sara C.⁴⁵,Alghamdi Wael A.⁶^ORCID,Alshaer Mohammad H.⁷^ORCID,Peloquin Charles A.⁷^ORCID,Avaliani Zaza²,Blumberg Henry M.¹³⁴,Kempker Russell R.¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

2. National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia, USA

3. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

4. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

5. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

6. Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia

7. College of Pharmacy, University of Florida, Gainesville, Florida, USA

Abstract

Although linezolid is effective for multidrug-resistant TB (MDR-TB) tuberculosis treatment, it is associated with cytopenias after 4 weeks of administration. Data on toxicities with long-term use of linezolid and drug pharmacodynamics in MDR-TB treatment are limited, and concerns about toxicity present barriers to wider implementation.

Funder

HHS | NIH | Fogarty International Center

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | National Center for Advancing Translational Sciences

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00408-22

Reference40 articles.

1. World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.

2. Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis

3. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

4. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.

5. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analyse pharmacologique du traitement des pneumopathies à Mycobacterium abscessus;Revue des Maladies Respiratoires;2024-01

2. Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review;Pathogens;2023-11-24

3. Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment;Pharmaceuticals;2023-11-08

4. Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies;Expert Review of Anti-infective Therapy;2023-05-08

5. Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review;Infectious Diseases and Therapy;2023-01-07